NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today

By August 25, 2011

(GLOBE NEWSWIRE) — NovaBay® Pharmaceuticals, Inc. (NYSEAmex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, is highlighted in the August 2011 issue of Cataract & Refractive Surgery Today.

The article, titled “Aganocide Compounds Show Activity Against Ophthalmic Agents,” outlines NovaBay’s development of Aganocide compounds for use as anti-infective agents to treat ophthalmic infections. Also covered are the Company’s recently completed Phase 2 clinical trial of its Aganocide NVC-422 for adenoviral conjunctivitis as well as a recent study of the activity of Aganocides NVC-727, NVC-638 and NVC-704 against ophthalmic pathogens.

Eric Donnenfeld, MD, chief medical editor of Cataract & Refractive Surgery Today, is quoted in the article regarding the Phase 2 clinical trial: “I have thoroughly reviewed the data analyses from this adenovirus conjunctivitis study and found them to be compelling, particularly as they relate to epidemic keratoconjunctivitis. As a practicing ophthalmologist who has participated in over 40 FDA studies, some involving anti-infectives to treat viral eye infections, I appreciate the need in the market for a product that can treat these serious eye conditions. I believe NVC-422 has the potential to make a difference in the lives of these patients.”

To read the entire article, please visit the following link: http://bmctoday.net/crstoday/pdfs/CRST0811_therapeutics.pdf

About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.

NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com

Investors:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

Investors and Media:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
212-825-3210
adam@investorrelationsgroup.com

Public Relations:
Laura Colontrelle
212-825-3210
laura@investorrelationsgroup.com

TOP